Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...

These aren't for the faint of heart.

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is set to give its latest quarterly earnings report on Wednesday, 2026-02-25. Here's what investors need to know before the announcement. Analysts estimate that ...

Investors with a lot of money to spend have taken a bearish stance on Recursion Pharmaceuticals (NASDAQ:RXRX). And retail traders should know. We noticed this today when the positions showed up on ...

In a recent social media post, Peter Ray, senior director of medicinal chemistry at Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), drew attention to a new article in WIRED from Veronique Greenwood ...

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.